NEWS
Advancements in Patient-Centered Care
Stay up to date with the latest advancements in oral oncolytics, medically-integrated oncology, and cancer care best practices.
![](https://www.ncoda.org/wp-content/uploads/2022/09/ncoda_horizontal_full_color1-min.png)
Mirati Therapeutics Announces U.S. FDA Accelerated Approval of KRAZATI™ (adagrasib) as a Targeted Treatment Option for Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) with a KRASG12C Mutation
December 14, 2022
![](https://www.ncoda.org/wp-content/uploads/2022/12/OPTA-Certification-1200-×-600-px-2.png)
![](https://www.ncoda.org/wp-content/uploads/2022/12/OPTA-Certification-1200-×-600-px-2.png)
New NCODA Program Equips Oncology Pharmacy Technicians with Premier Certification
December 8, 2022
![](https://www.ncoda.org/wp-content/uploads/2022/09/ncoda_horizontal_full_color1-min.png)
![](https://www.ncoda.org/wp-content/uploads/2022/09/ncoda_horizontal_full_color1-min.png)
![](https://www.ncoda.org/wp-content/uploads/2022/09/ncoda_horizontal_full_color1-min.png)
![](https://www.ncoda.org/wp-content/uploads/2022/09/ncoda_horizontal_full_color1-min.png)
![](https://www.ncoda.org/wp-content/uploads/2022/09/ncoda_horizontal_full_color1-min.png)
![](https://www.ncoda.org/wp-content/uploads/2022/09/ncoda_horizontal_full_color1-min.png)
![](https://www.ncoda.org/wp-content/uploads/2022/09/ncoda_horizontal_full_color1-min.png)
![](https://www.ncoda.org/wp-content/uploads/2022/09/ncoda_horizontal_full_color1-min.png)
Libtayo® (cemiplimab-rwlc) in Combination with Chemotherapy Approved by the FDA as First-line Treatment for Advanced Non-small Cell Lung Cancer (NSCLC)
November 14, 2022
![](https://www.ncoda.org/wp-content/uploads/2022/09/ncoda_horizontal_full_color1-min.png)
![](https://www.ncoda.org/wp-content/uploads/2022/09/ncoda_horizontal_full_color1-min.png)
![](https://www.ncoda.org/wp-content/uploads/2022/09/ncoda_horizontal_full_color1-min.png)
![](https://www.ncoda.org/wp-content/uploads/2022/09/ncoda_horizontal_full_color1-min.png)
![](https://www.ncoda.org/wp-content/uploads/2022/09/ncoda_horizontal_full_color1-min.png)
![](https://www.ncoda.org/wp-content/uploads/2022/09/ncoda_horizontal_full_color1-min.png)
![](https://www.ncoda.org/wp-content/uploads/2022/09/ncoda_horizontal_full_color1-min.png)
![](https://www.ncoda.org/wp-content/uploads/2022/09/ncoda_horizontal_full_color1-min.png)
U.S. FDA Approves TECVAYLI™ (teclistamab-cqyv), the First Bispecific T-cell Engager Antibody for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma
November 1, 2022
![](https://www.ncoda.org/wp-content/uploads/2022/10/NYOH-Rally_large-file.png)
![](https://www.ncoda.org/wp-content/uploads/2022/10/NYOH-Rally_large-file.png)
NYOH Leads Rally In Response to Life Threatening Policy Change That Effects Cancer Patients
October 13, 2022
![](https://www.ncoda.org/wp-content/uploads/2022/09/ncoda_horizontal_full_color1-min.png)
![](https://www.ncoda.org/wp-content/uploads/2022/09/ncoda_horizontal_full_color1-min.png)
![](https://www.ncoda.org/wp-content/uploads/2022/09/ncoda_horizontal_full_color1-min.png)
![](https://www.ncoda.org/wp-content/uploads/2022/09/ncoda_horizontal_full_color1-min.png)
![](https://www.ncoda.org/wp-content/uploads/2022/09/ncoda_horizontal_full_color1-min.png)
![](https://www.ncoda.org/wp-content/uploads/2022/09/ncoda_horizontal_full_color1-min.png)
![](https://www.ncoda.org/wp-content/uploads/2022/09/ncoda_horizontal_full_color1-min.png)
![](https://www.ncoda.org/wp-content/uploads/2022/09/ncoda_horizontal_full_color1-min.png)
Children with Chronic Graft Versus Host Disease (cGVHD) May Now Be Prescribed IMBRUVICA® (ibrutinib)
October 3, 2022
![](https://www.ncoda.org/wp-content/uploads/2022/09/RELEASE_graphic-5.png)
![](https://www.ncoda.org/wp-content/uploads/2022/09/RELEASE_graphic-5.png)
BIDEN MOONSHOT INITIATIVE FOCUSED ON CHANGING CANCER LANDSCAPE
September 13, 2022
![](https://www.ncoda.org/wp-content/uploads/2022/09/ncoda_horizontal_full_color1-min.png)
![](https://www.ncoda.org/wp-content/uploads/2022/09/ncoda_horizontal_full_color1-min.png)
![](https://www.ncoda.org/wp-content/uploads/2022/09/ncoda_horizontal_full_color1-min.png)
![](https://www.ncoda.org/wp-content/uploads/2022/09/ncoda_horizontal_full_color1-min.png)
![](https://www.ncoda.org/wp-content/uploads/2022/09/ncoda_horizontal_full_color1-min.png)
![](https://www.ncoda.org/wp-content/uploads/2022/09/ncoda_horizontal_full_color1-min.png)
![](https://www.ncoda.org/wp-content/uploads/2022/09/ncoda_horizontal_full_color1-min.png)
![](https://www.ncoda.org/wp-content/uploads/2022/09/ncoda_horizontal_full_color1-min.png)
Incyte Announces FDA Approval of Pemazyre® (pemigatinib) as the First and Only Targeted Treatment for Myeloid/Lymphoid Neoplasms (MLNs) with FGFR1 Rearrangement
September 12, 2022
![](https://www.ncoda.org/wp-content/uploads/2022/09/ncoda_horizontal_full_color1-min.png)
![](https://www.ncoda.org/wp-content/uploads/2022/09/ncoda_horizontal_full_color1-min.png)
![](https://www.ncoda.org/wp-content/uploads/2022/09/ncoda_horizontal_full_color1-min.png)
![](https://www.ncoda.org/wp-content/uploads/2022/09/ncoda_horizontal_full_color1-min.png)
![](https://www.ncoda.org/wp-content/uploads/2022/09/ncoda_horizontal_full_color1-min.png)
![](https://www.ncoda.org/wp-content/uploads/2022/09/ncoda_horizontal_full_color1-min.png)
![](https://www.ncoda.org/wp-content/uploads/2022/09/ncoda_horizontal_full_color1-min.png)
![](https://www.ncoda.org/wp-content/uploads/2022/09/ncoda_horizontal_full_color1-min.png)
SpringWorks Therapeutics Announces Data from Phase 3 DeFi Trial Evaluating Nirogacestat in Adult Patients with Progressing Desmoid Tumors at the European Society for Medical Oncology (ESMO) Congress 2022
September 12, 2022
![](https://www.ncoda.org/wp-content/uploads/2022/09/LinkedIn-Article-Image-1200-×-645-px.png)
![](https://www.ncoda.org/wp-content/uploads/2022/09/LinkedIn-Article-Image-1200-×-645-px.png)
MAINE CONTINUES REFORM FOR PATIENTS
September 6, 2022
![](https://www.ncoda.org/wp-content/uploads/2022/09/ncoda_horizontal_full_color1-min.png)
![](https://www.ncoda.org/wp-content/uploads/2022/09/ncoda_horizontal_full_color1-min.png)
![](https://www.ncoda.org/wp-content/uploads/2022/09/ncoda_horizontal_full_color1-min.png)
![](https://www.ncoda.org/wp-content/uploads/2022/09/ncoda_horizontal_full_color1-min.png)
![](https://www.ncoda.org/wp-content/uploads/2022/09/ncoda_horizontal_full_color1-min.png)
![](https://www.ncoda.org/wp-content/uploads/2022/09/ncoda_horizontal_full_color1-min.png)
![](https://www.ncoda.org/wp-content/uploads/2022/09/ncoda_horizontal_full_color1-min.png)
![](https://www.ncoda.org/wp-content/uploads/2022/09/ncoda_horizontal_full_color1-min.png)
Children with Chronic Graft Versus Host Disease (cGVHD) May Now Be Prescribed IMBRUVICA® (ibrutinib)
August 26, 2022
![](https://www.ncoda.org/wp-content/uploads/2022/08/AJMC-web-graphic-600x300px-1.png)
![](https://www.ncoda.org/wp-content/uploads/2022/08/AJMC-web-graphic-600x300px-1.png)
Defining Appropriate Quality Performance Metrics for Pharmacies Dispensing Oral Oncology Therapies
August 19, 2022
RESOURCES
Cost Avoidance Waste Tracker
PQI in Action
OCE Sheets
IVE Sheets
Treatment Support Kits
PQI Podcast
Members
Member Resources
OPTA
Committees
Member Login
Events
Webinars
Spring Forum
Oncology Institute
PSO Annual Meeting
Fall Summit
315-655-4640
P.O. Box 468
Cazenovia, NY 13035
NURSE RESOURCES
Through collaboration between oncology nurses throughout North America, these resources are available to all NCODA members.